Testing With FullTerm™, The Fetal Fibronectin Test
The FDA has approved FullTerm™, The Fetal Fibronectin Test, for use as an aid in assessing the risk for preterm birth in women with or without symptoms of preterm labor.
IN THIS SECTION
An easy, 4-step procedure for collecting specimens, including instructions for ensuring accurate patient results.
Essential reimbursement codes associated with FullTerm, The Fetal Fibronectin Test.
Information for laboratory technologists, including step-by-step instructions for using the TLiIQ® System to provide test results to healthcare providers.
The QuikCheck fFN Test is not approved for sales and marketing in the U.S. or licensed for sale in Canada.
A simple, reliable test that determines the risk of preterm birth.
